Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ACAD
ACADIA Pharmaceuticals Inc.
Healthcare | Biotechnology
$20.94-0.33 (-1.55%)as of 2026-07-14 09:08 UTC
Market Cap$3.6B
Volume1.24M
EPS (TTM)$2.30
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a $3.6B biotechnology company trading at $20.94 (−1.6% today) — 9.1× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-14 09:08 UTC.
52-Week Range
Low $19.69High $28.35
What ACADIA Pharmaceuticals Inc. does
Ultragenyx Pharmaceutical is a biopharmaceutical company developing treatments for neurological and rare diseases. The company's two main commercial products are NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, which together generated net product sales of $1,071.5 million in 2025, up from $957.8 million in 2024.
Summarized from ACADIA Pharmaceuticals Inc.’s SEC filings · Read the filing ↗
Ultragenyx Pharmaceutical is a biopharmaceutical company developing treatments for neurological and rare diseases.
What is ACAD's valuation?
ACAD trades at $20.94, 9.10× trailing earnings, 32.10× EV/EBITDA, as of 2026-07-14.
When did ACAD last file with the SEC?
ACADIA Pharmaceuticals Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-29. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings and public market data feeds, fetched 2026-07-14 09:08 UTC. This page is also available as JSON at /api/data?ticker=ACAD and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACAD and 3,500+ tickers.
